VNDA — Vanda Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $355.59m
- -$38.55m
- $192.64m
- 79
- 47
- 86
- 81
Annual cashflow statement for Vanda Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 116 | 23.3 | 33.2 | 6.28 | 2.51 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 12.1 | 15.1 | 18.7 | 15.8 | 9.31 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.13 | 4.32 | 2.74 | 6.07 | -0.747 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 45.9 | 51.8 | 64.2 | 32 | 12.8 |
| Capital Expenditures | -1.02 | -1.79 | -0.552 | -0.679 | -0.383 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -67.3 | -39.7 | -76.1 | 50.6 | -11.7 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -68.3 | -41.5 | -76.7 | 49.9 | -12.1 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 6.26 | 5.63 | 3.55 | 0.734 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -16.1 | 16 | -9.02 | 82.9 | 0.792 |